Celcuity (NASDAQ:CELC) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Celcuity (NASDAQ:CELC) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $27.00 price objective on the stock.

CELC has been the topic of several other research reports. Leerink Partnrs raised Celcuity to a strong-buy rating in a report on Monday, July 22nd. Stifel Nicolaus reduced their price objective on Celcuity from $40.00 to $39.00 and set a buy rating on the stock in a report on Thursday. Craig Hallum reaffirmed a buy rating and set a $27.00 price objective (up previously from $25.00) on shares of Celcuity in a report on Thursday, May 16th. Needham & Company LLC reduced their price objective on Celcuity from $24.00 to $23.00 and set a buy rating on the stock in a report on Friday, May 31st. Finally, SVB Leerink initiated coverage on Celcuity in a report on Monday, July 22nd. They set an outperform rating and a $29.00 price objective on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Buy and an average target price of $29.00.

Celcuity Stock Up 4.9 %

Shares of CELC opened at $16.55 on Thursday. The company has a market capitalization of $580.92 million, a P/E ratio of -5.95 and a beta of 0.81. The company has a debt-to-equity ratio of 0.28, a current ratio of 11.23 and a quick ratio of 11.23. Celcuity has a one year low of $8.39 and a one year high of $22.19. The business’s 50 day simple moving average is $16.70 and its 200-day simple moving average is $16.84.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same period last year, the company earned ($0.66) earnings per share. As a group, sell-side analysts predict that Celcuity will post -2.86 EPS for the current fiscal year.

Institutional Trading of Celcuity

Several institutional investors and hedge funds have recently made changes to their positions in the business. Driehaus Capital Management LLC raised its position in shares of Celcuity by 62.3% during the 2nd quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock valued at $3,351,000 after acquiring an additional 78,525 shares during the last quarter. Blue Owl Capital Holdings LP bought a new stake in shares of Celcuity during the 2nd quarter valued at $1,065,000. Marshall Wace LLP raised its position in shares of Celcuity by 40.0% during the 2nd quarter. Marshall Wace LLP now owns 152,291 shares of the company’s stock valued at $2,495,000 after acquiring an additional 43,476 shares during the last quarter. Samlyn Capital LLC raised its position in shares of Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after acquiring an additional 637,190 shares during the last quarter. Finally, Quest Partners LLC raised its position in shares of Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after acquiring an additional 1,379 shares during the last quarter. Institutional investors own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.